US-traded European stocks edged lower Friday morning, as a decline in chip designer Arm and steelmaker ArcelorMittal outweighed gains in several biotech names. The S&P Europe Select ADR Index, which tracks American depositary receipts of European companies, fell 0.4% to 1,883.22.
Arm Holdings, the British chip designer that went public in the US last year, dropped 4%, while Luxembourg-based steel giant ArcelorMittal slid 3.5%. Norway's oil major Equinor fell 1.3%, and UK bank Barclays also declined 1.3%. On the upside, biotech stocks led the gainers: Compass Pathways rose 5.6%, Evaxion climbed 5.4%, Abivax added 4.5%, and gene-therapy developer Autolus gained 2.8%.
What Are ADRs and Why Do They Matter?
American depositary receipts, or ADRs, are US-traded certificates that represent shares in foreign companies. They allow US investors to buy and sell international stocks on American exchanges, in dollars, without dealing with foreign currencies or overseas brokerages. The S&P Europe Select ADR Index bundles many of these into a single benchmark.
Because ADRs trade during US market hours, their prices can diverge from the underlying shares traded in Europe. This is partly due to currency translation: the local share price is converted into dollars using the euro-dollar or pound-dollar exchange rate, and the ADR-to-share ratio also plays a role. When foreign-exchange markets are active, ADR moves can appear larger than the local stock's session, even if the European market had a relatively calm day.
Friday's index dip, while modest, highlights how a few large, economically sensitive names can drag the whole index lower, even when many smaller stocks are rising. Arm and ArcelorMittal are widely held by institutional investors, so their declines have an outsized impact on the index's value.
Biotech Shines Amid Broader Weakness
The biotech sector provided a bright spot. Compass Pathways, a UK-based mental health care company, jumped 5.6%. Evaxion, a Danish vaccine developer, rose 5.4%, and French biotech Abivax added 4.5%. Autolus, a UK gene-therapy firm, gained 2.8%. These gains suggest investor interest in smaller, high-growth healthcare names, even as broader market sentiment turned cautious.
The divergence between biotech winners and industrial losers reflects a common pattern: when economic uncertainty rises, investors often rotate out of cyclical stocks like steel and energy and into defensive or growth-oriented sectors like biotech. However, the index's overall decline shows that the weight of the losers was greater than the sum of the winners.
What It Means for Investors
For everyday investors, the 0.4% dip in the ADR index is a reminder that ADR performance can diverge from what local European headlines suggest. The currency layer is often the reason: a strong dollar can make ADRs look weaker even if the underlying European shares are flat, and vice versa.
Investors holding ADRs should also be aware of liquidity differences. ADRs trade during US hours, when trading volumes can be thinner than in Europe, leading to sharper price swings. This is especially true for smaller companies like Compass Pathways or Evaxion, where a few large trades can move the stock significantly.
Friday's moves also underscore the importance of diversification. While Arm and ArcelorMittal dragged the index lower, biotech names offered gains. A portfolio that includes both cyclical and defensive stocks can help smooth out such volatility.
Broader Market Context
The ADR index's decline comes amid a mixed session for global markets. In recent weeks, tech stocks have faced pressure from concerns about AI valuations and interest rate uncertainty. Meanwhile, oil prices have tumbled, with WTI crude falling below $70 a barrel, weighing on energy stocks like Equinor. The yen has also tested intervention zones, adding to currency market jitters.
For European stocks specifically, the backdrop includes sticky inflation in the US, which has revived fears of further Federal Reserve rate hikes. Higher US rates can strengthen the dollar, making ADRs more expensive for dollar-based investors and potentially dampening demand.
Looking Ahead
Investors will be watching next week's economic data, including US jobs reports and European inflation figures, for clues on central bank policy. Any surprises could trigger further currency moves, which in turn would affect ADR prices. For now, the S&P Europe Select ADR Index's modest decline suggests a cautious but not panicked market, with sector-specific stories driving individual stock moves.
